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Optimization of the fill-finish process for a biotherapeutic is imperative for the highest 
quality drug product.  Chemical and physical degradation must be fully characterized as an 
enzyme progresses towards commercialization to design a fully optimized process.  To avoid 
degradation and/or sensitivity to the filling process of an enzyme, pharmaceutical scientists 
utilize stabilizing excipients as tools to mitigate known chemical or structural weaknesses; 
however, little work has been published on process-related stabilization techniques when the 
route of administration dictates the exclusion of key stabilizing excipients.  The goal of this 
thesis is to provide guidance in selecting key factors impacting enzyme stability in fill-finish 
processes in the absence of excipients.  The effect of shear stress applied to an enzyme solution 
was studied in the presence of various interfaces, including air, stainless steel, and tubings 
commonly used in manufacturing.  Although interfacial interactions and aggregation pathways 
are considered to be enzyme-specific, this work will allow researchers to focus on key conditions 
affecting stability of proteins in this process.  Factors studied here include exposure of the 
formulation to shear stress from several models with increasing interfacial complexity.  The most 
simplistic model applied a specific shear stress through a microfluidic chip, exposing the enzyme 
solution to high levels of shear for a short period of time.  A cone and plate rotational rheometer 
was used to study shear applied to an enzyme solution for up to ten minutes with the addition of 
an air-water interface.  Lastly, a recirculation model was employed to study the interaction with 
tubing surfaces and the shear stresses caused by peristaltic pumping over time.  Several 
analytical assays were employed to understand destabilization caused by these stress models, and 
were extended to lead to an overall understanding of the impact of various process-related 
stresses.  An enzyme solution exhibits the most dramatic change when exposed to the peristaltic 
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recirculation pumping model, with the most significantly destabilizing factor being the use of a 
thermoplastic elastomer tubing surface.  The other shear stress models did not produce trends in 
measured responses, indicating that the associated levels of stress with these models are below 
the amount necessary to irreversibly alter stability.  Methods to measure and characterize 
aggregation for the recirculation models across a large dynamic range showed dramatic changes 
with increasing exposure time, resulting in increased aggregate populations over the length of 
pumping time.  The flow imaging data captured high levels of particles shed from the tubing 
material in the 1-100 µm size-range. These particles could act as heterogeneous nucleation sites, 
and could explain the increase in aggregation in enzyme solution with these tubing types.  The 
presence of unique multimeric soluble enzyme aggregates was observed in the thermoplastic 
elastomer tubings, indicating not only that they are deleterious in terms of colloidal stability, but 
presumably they are formed via different pathways.  Silicone tubings performed with a higher 
standard in recirculation models than thermoplastic tubings. Silicone tubings produced a very 
low amount of subvisible particulate shedding, undetectable multimeric aggregate species, and a 
better overall visual appearance after recirculation for up to four hours.  In summary, notable 
enzyme solution instability was not related to the stress of shear in a flow field alone, but rather 
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A.1. Importance of Proteins (Enzymes) as Potential Therapeutics 
Enzymes are integral to many of the mechanisms of human metabolism and health, and it is 
often devastating when genetic or other forms of disease prevent the body from producing the 
enzymes needed.  Many inherited genetic diseases are caused by the inability of the body to 
produce certain enzyme(s).  Therefore, one of the ways that the field of pharmaceutical sciences 
has responded is by developing functioning enzyme replacement therapy (ERT) for individuals 
who have missing or non-functioning enzyme(s).  For example, Gaucher disease leads to the 
buildup of cellular debris in the lysosomes due to the lack of a metabolic enzyme called 
β-glucocerebrosidase, causing damage to the spleen, liver and bone marrow.  In response, several 
ERT’s such as Cerezyme®, VPRIV®, and Elelyso® have been developed and approved to meet 
this previously unmet medical need.  With all the excitement surrounding the promise and 
development of biotherapeutics, the truth is that enzymes are inherently unstable. Thus, the goal 
to successfully manufacture, process and provide a suitable shelf-life of an enzyme drug product 
is not a trivial or inexpensive task for biopharmaceutical companies.  This is because enzymes 
are susceptible to chemical and physical degradation in any of the steps along the manufacturing 
process up to application in treatment1. 
Chemical and physical degradation pathways are enzyme-specific.  An enzyme has a 
complex structure made up of long chains of uniquely coded amino acids.  Each amino acid has 
its own chemical behavior in solution depending on its identity and location within the primary, 
secondary, and tertiary structures.  A reactive moiety located in an accessible site of the enzyme 
higher-order structure may undergo a destabilizing chemical reaction, including deamidation, 
oxidation or a disulfide bond exchange reaction2.  If any of these modifications were to occur in 
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a detrimental position, the enzyme could become denatured and no longer maintain its biological 
activity or therapeutic effect.  Physical degradation of a native enzyme involves higher-order 
conformational changes to form irreversible protein aggregates with different sizes, 
secondary/tertiary structures, covalent modifications, or morphologies, which can lead to 
irreversible inactivation of the enzyme3.  Whatever the resulting classification of aggregates, they 
produce irreversible agglomeration either with a native monomer, a similarly compromised 
molecule, or some other impurities4. This agglomeration can escalate and eventually grow to the 
point of becoming insoluble particulate that can even be visible to the eye.  To develop the 
enzyme as a therapeutic agent, it is necessary to fully understand its stability sensitivities during 
all stages of development, including manufacturing, filling, and packaging processes in order to 
mitigate them and produce a successfully active drug product5.   
 
A.2. Importance of Protein Stability during Filling of Primary Packaging: flow and contact-part 
compatibility 
Because fill-finish is the final step in manufacturing a biotherapeutic, it is imperative that the 
stresses imposed during the process should not lead to aggregation and visible particles in the final 
drug product.  Aggregation can lead to a decrease in potency due to a lower dose in solution and 
an induction of immunogenicity6; 7; 8.  The filling process consists of bulk product pooling and 
aseptic filling via a sterile filtration step through a 0.22 µm pore-size filter.  This process requires 
the transfer of a large amount of liquid drug substance through various tubings and contact parts, 
imposing stress on the molecule, especially during filtration and filling steps.  If aggregates or 
particulates below the 0.22 µm filter cut-off still remain after filtration, they could act as seeds for 
nucleation of protein aggregates in the final product during shipping, handling, and storage. 
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Therefore, it is necessary to fully characterize any undesirable effects of stress generated by 
pumping or interfacial interactions9; 10. In the fluid mechanical sense, shear stress is created by 
friction between the solution and the tube surface during flow. A shear stress varies linearly across 
the diameter of tubing with zero shear stress experienced in the center and the maximum shear 
stress at the wall11.  Therefore, a constant gradient of movement occurs in a flowing solution 
containing the enzyme molecules.  As the enzyme molecules in solution gain momentum, the 
incidence of molecular collisions that can compromise protein conformational stability increases.  
If collisions cause an enzyme to conform to a partially unfolded state, the exposed hydrophobic or 
chemically labile amino acid residues can promote physical aggregation. 
During manufacturing and commercial packaging processes, the drug substance comes into 
contact with many different types of surfaces.  These surfaces can be plastic, glass and steel that 
are used at various stages of the manufacturing process.  It is of utmost importance to ensure that 
materials used in the final fill-finish process exhibit the highest quality and compatibility profile 
with low or undetectable leachables or particulates. This is because introduction of leachables can 
compromise product maximum stability and safety.  Bee et al.12 concluded that destabilization of 
protein in formulation could be mitigated to produce the best outcome by formulation adjustments, 
process modifications, or material changes.  For the formulation presented herein, process and 
material changes are the only opportunity to produce the best outcome.     
The goal of this work was to observe the effects of both shear stress and tubing interfacial 
interactions on the stability of an enzyme in the absence of sugar or surfactant with the intent to 
design an optimized fill-finish process.  To study increasingly complex applications of shear, 
models were developed using a pressure differential viscometer, the m-VROC™, a rotational 
rheometer using cone and plate geometry, and a peristaltic pumped recirculation model with 
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commonly used tubing materials.  Various analytical tools were used to elucidate enzyme 
instability, including RP-HPLC, SEC-HPLC, CD, DLS, MFI, and turbidity measurements.  
Although shear stress does not significantly influence the enzyme stability, the clearest factor 
causing instability was the exposure to a specific tubing surface.  The interactions of enzyme 
solution with various marketed tubing materials produced different outcomes when pumped in the 
recirculation model presented here. The results showed that there is an advantage of using one 
material over another; thus, the selection of tubing material should be considered and tested 
carefully when designing the filling process.   
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B. EXPERIMENTAL SECTION  
B.1. Reagents and Solutions 
The enzyme used in this study was formulated at a 30 mg/mL protein concentration in 
Sodium Phosphate buffer at pH 6.5, including various salts found in the intracerebral space 
including Sodium Chloride, Potassium Chloride, Calcium Chloride, and Magnesium Chloride, 
called artificial cerebral spinal fluid, or aCSF buffer.  aCSF buffer used in the pumping 
experiments was identical to the enzyme biotherapeutic formulation buffer solution without the 
enzyme.  The enzyme was provided by BioMarin Pharmaceutical Inc. (Novato, CA, USA). 
All salts used were purchased from VWR® (Radnor, PA, USA) with a multicompendial 
grade.  Salts used to prepare SEC-HPLC mobile phase and formulation buffers were purchased 
from VWR® (Radnor, PA, USA). All solvents and solutions used for RP-HPLC including 
Tween-20, Methanol (MeOH), Sodium Hydroxide (NaOH), Acetonitrile (ACN), HPLC-grade 
water, and Trifluoroacetic acid (TFA) were obtained from Sigma-Aldrich® (St. Louis, MO, 
USA).   
 
B.2. Measuring the Effect of Shear using the m-VROC™   
The stress experiment was carried out once using the pressure differential m-VROC™ 
Viscometer (Rheosense, San Ramon, CA, USA) and was the most highly controlled system for 
applying a shear stress.  The m-VROC™ is a closed system comprised of a glass gastight syringe 
connected to a stainless steel channel chip, mVROC-C05, equipped with several pressure 
sensors, which provide feedback to measure various properties of the solution at a controlled 
temperature.  The test was performed in the absence of an air interface, allowing for the accurate 
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exposure of a solution to very high shear rates for a short burst of time.  The only surfaces that 
the biotherapeutic encountered were a gastight borosilicate type I glass of the 10 mL syringe 
with a PTFE plunger and a stainless steel channel inside the chip for measuring pressure.   
The shear rates experienced by the protein formulation were high, up to 200 ks-1; but because 
the internal volume of the chip was only 1.2 mm3, the residence time was short, leading to a γ’θ 
parameter in the range of 103.   
 
B.3. Measuring the Effect of Shear using a Rotational Rheometer 
A Bholin CVO100 cone and plate rheometer (Malvern, Malvern, UK) was used to expose the 
biotherapeutic enzyme to both shear and an air interface, which is known to be a factor for 
causing protein damage or aggregation13; 14.  1.2 mL of  the neat 30 mg/mL enzyme was 
introduced to a 4/40 cone and plate system lowered to a 150 mm gap height.  Once the enzyme 
solution was introduced and allowed to thermally equilibrate for 2 minutes, the system was 
brought to a constant shear rate for 10 minutes.  The sample was collected directly after the 
application of a constant shear rate for analysis using various assays described in the analysis 
section (see below).   
The enzyme test solution was held in place by surface tension and the solution was exposed 
to an air interface along the height of the gap between the cone and the plate.  As the cone begins 
to apply a constant shear rate, the rate should stay below the test-solution point of ejection.  The 
enzyme solution was water-like; therefore, the shear rates applied by the rotational rheometer 
were lower than the mVROC™  with the maximum shear rate at 1 x 103 s-1.   The limitation of 
the relatively lower shear rate applied was balanced by the application of a 10-minute exposure 
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time, which was long in comparison to the mVROC™ and it was only limited by rate of 
evaporation from the air interface.  This method led to a γ’θ parameter ranging from 103 to 105. 
 
B.4. Measuring the Effect of Shear and Process-specific Surfaces during Pumping 
The pumping process of the enzyme solution was the most complex system to assess and 
model; this was due to the presence of interfacial phenomena experienced by the enzyme 
solution as well as the stress of flow applied by a peristaltic pump.  All experiments were 
completed in a laminar flow biosafety cabinet to minimize external particulate introduction to the 
system.  A peristaltic Flexicon PF6 pump, (Watson Marlow, Wilmington, MA, USA) was 
calibrated to dispense 5.4 mL, using a specific gravity of 1.0148 and a 2-second pause time.  
Biotherapeutic enzyme solution at 30 mg/mL or aCSF buffer was measured and added to a 
particle-free, sterile 50 mL conical container for recirculation and a new piece of treated tubing 
was used for each experimental replicate.  Solution was continuously pumped through 1-meter of 
tubing at 100 RPM.  As each time point was reached (i.e., 15 min, 60 min, 120 min, 180 min and 
240 min),  2 mL of solution was removed for analysis.  Samples were immediately frozen 
at -50 °C and held until analysis was performed. 
Tubing was prepared by cutting into 1-meter segments followed by a rinsing with Milli-Q 
water, and then it was dried with Nitrogen gas to remove any settled particles from the contact 
surface.  After drying, all tubing segments were autoclaved at 121 °C for 30 min and cooled prior 
to use.  To expose the enzyme solution to different shear rates, two different tubing inner-
diamaters (IDs) were used in these experiments: 1.6 mm and 3.2 mm.  The 1.6 mm ID tubing 
was used to represent the worst-case or high-stress flow dynamics with a caculated γ’θ parameter 
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range of 106 to 107.  The 3.2 mm ID tubing had a caculated γ’θ parameter range of 105 to 106.  
Tubing types and their characteristics are summarized in Table 1. 
It is important to note that the PureWeld®XL tubing was difficult to use in the peristaltic 
pump as its outer surface was smooth, causing the tubing segment to travel in the pump head 
over time, even with the use of the appropriately sized holding block.  To keep the tubing in 
place during the recirculation experiment, it had to be bent and taped to the pump itself to 
prevent from slipping.  Additionally, at every time point, it was often repositioned and re-taped 
to ensure the tubing did not move from the recirculation vessel over time to introduce unwanted 




Table 1.  Tubings investigated and their properties 
Manufacturer Identity Physical Properties 




















1Durometer is a measure of material hardness 
2Watson Marlow, Wilmington, MA, USA  
3Saint-Gobain, Malvern, PA, USA 
 
 
Table 2. RP HPLC method gradient 
a) Sample Method Gradient b) Column Cleaning Gradient 
Time 
(min) %B Flow Rate (mL/min) Time (min) %B Flow Rate (mL/min) 
0 10 0.75 0 10 0.5 
3.5 32 0.75 2.8 10 0.5 
15 55 0.75 3 10 1 
18.5 55 1.3 6.5 52 1 
20.5 10 1.3 10 70 1 
26 10 1.3 12.5 70 1.3 
   17 10 1.3 




B.5. Turbidity Measurement 
The overall aggregation was monitored by measuring absorbance at 550 nm using a 
SpectraMax M2e Microplate reader (Molecular Devices, Sunnyvale, CA, USA).  200 µL of neat 
protein solution was pipetted to a 96-well transparent plate for measurement.  
 
B.6. Micro-Flow Imaging 
Subvisible particulate analysis was carried out using either an MFI5200 or MFI4200 
instrument (ProteinSimple, San Jose, CA, USA) in conjunction with MVSS software.  
Approximately 0.75 mL of either the neat protein or buffer test sample was loaded into the 
instrument with a 1 mL pipette tip.  The sample volume then flowed through a 100 µm (SP3), 1.6 
mm Silane coated flow cell (Part No. 4002-002-001) for analysis.  The instrument suitability 
check was performed using a 5 µm Duke Standard™ bead (Thermo Scientific™, Waltham, MA, 
USA).  The flow cell was flushed with 15–25 mL of particle-free water after each measurement 
run, and a water check was performed to confirm flow cell cleanliness with a criteria of  
< 200 particles/mL between every run.  Protein samples were run neat except those with a highly 
visible turbidity.  Pumped samples with high turbidity were diluted 1:5 using particle free aCSF 
buffer to ensure accurate particle counting. 
 
B.7. Size-Exclusion Chromatography  
Quantitative analyses of monomer and soluble higher order molecular weight aggregates 
were determined using a Waters HPLC system with column heater, sample refrigeration, 
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continuous mobile phase degasser, auto injector, and UV detector (Waters, Orlando, FL, USA).  
Protein solution was diluted to 1 mg/mL in formulation buffer and pre-filtered using a 0.2 µm 
PVDF filter (MilliporeSigma®, Burlington, MA, USA).  Finally, 20 µg in 20 µL of each test 
sample was injected onto a TSK gel G3000SWxl, 7.8 x 30 cm column (Tosoh Bioscience, South 
San Francisco, CA, USA).  An isocratic method was used at 1 mL/min for 25-minute run time in 
a 10 mM Sodium Phosphate, 300 mM NaCl Mobile Phase at pH 7.4, monitored at 214 nm.  The 
protein peaks were integrated using Empower3 software (Waters, Orlando, FL, USA) and the 
result for each experiment was reported as % Area normalized to the unstressed or the initial 
protein peak. 
 
B.8. Reversed Phase Chromatography 
Quantitative analyses of monomer and various chemical degradant contents was performed 
using a polystyrene-divinylbenzene (PS-DVB) reversed-phase column: 4000Å, 5 µm particle 
size, and 50 x 4.6 mm column (Agilent Technologies, Santa Clara, CA, USA).  At the time of 
analysis, the assay was unqualified and meant to aid only in viewing a change in the “post-peak.”  
Although identity of the degradation peaks was unestablished at the time; these degradants had 
previously been implicated in some forced degradation studies (data not shown).  Results are 
reported as % Area, and are normalized to the initial, or unstressed protein for each experimental 
replicate as some variability has been seen with the results.   
A Waters® Alliance HPLC system was used, equipped with a column heater set at 50 ± 2 °C, 
sample refrigeration set at 6 ± 3 °C, a continuous mobile phase degasser, auto injector, and a UV 
detector monitoring 214 nm (Waters®, Orlando, FL, USA).  Chromatograms were integrated 
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using Empower3 software, (Waters®, Orlando, FL, USA).  Neat protein solution was diluted to 
1 mg/mL in aCSF formulation buffer and pre-filtered using a 0.2 µm PVDF syringe filter 
(MilliporeSigma®, Burlington, MA, USA).  
Samples were prepared for injection by mixing 20 µL of the diluted and filtered 1 mg/mL 
protein, 20 µL 0.05% v/v Tween-20, and 160 µL 500 mM Tris base with 0.05% Tween-20 
solutions.  30 µL of this sample mixture was injected onto the column using a gradient method as 
described in Table 2.  Mobile phase A was comprised of 90% Water, 10% ACN with 0.1% TFA, 
and mobile phase B was comprised of 80% ACN, 20% Water, and 0.09% TFA.  Each sample 
injection was followed by a 100 µL injection of cleaning solution, which was comprised of 
1.0 M NaOH with 20% MeOH run using the column cleaning gradient found in Table 2. 
 
B.9. Circular Dichroism (CD) Spectroscopy 
CD spectra were collected using a J-1500 CD (Jasco, Tokyo, Japan) equipped with a Peltier 
element and an autosampler.  CD spectra (285–195 nm) were measured in a 0.1 mm quartz cell 
with a scanning speed of 20 nm/min, a D.I.T. of 4 sec, a data pitch of 0.5 mm, and 1 nm 
bandwidth.  Sample spectra were averaged over 2–3 accumulations and buffer correction was 
applied by subtraction using the aCSF buffer spectrum.  The molar ellipticity was calculated 
using a molecular weight of 68 kDa in the Spectra Analysis software (Jasco®, Tokyo, Japan).  
Samples were prepared by diluting the neat enzyme sample with aCSF buffer to either 0.5 or 
1 mg/mL concentration, for the 1 mm and 0.1 mm flow cell, respectively.   Sample solutions 




B.10. Dynamic Light Scattering (DLS) 
A Zetasizer-APS (Malvern, Malvern, UK) was used for size measurement analysis of protein 
samples.  Protein samples were diluted to 1 mg/mL using aCSF buffer and filtered using a 
0.2 µm syringe filter (MilliporeSigma®, Burlington, MA, USA) prior to loading 75 µL onto a 96-





C.1. Calculation of γ’θ Parameter to Normalize Shear Across Platforms 
Three different models were used to apply a shear stress and the unitless γ’θ parameter was 
determined for each method using Equation 1 to allow for a comparison across methods.  Each 
type of experiment was performed with increasing complexity, allowing the γ’θ parameter to 
distinguish interfacial factors from shear stress alone across the models used.  This term takes 
into account the applied shear rate and applied stress time, which both are important parameters 
to compare among models, and was used by Charm and Lai15 to highlight that importance. 
 
Equation 1:  𝛾𝛾′𝜃𝜃 = 𝑠𝑠ℎ𝑒𝑒𝑒𝑒𝑒𝑒 𝑒𝑒𝑒𝑒𝑟𝑟𝑒𝑒, 𝑠𝑠−1 (𝛾𝛾′) × 𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑠𝑠𝑒𝑒𝑒𝑒𝑒𝑒 𝑟𝑟𝑡𝑡𝑡𝑡𝑒𝑒, 𝑠𝑠 (𝜃𝜃) 
 
The calculation of γ’θ parameter in m-VROC™ required an understaning of the residence 
time inside the mVROC-C05 chip to arrive at the θ parameter for Equation 1.  The shear stress 
experienced by the enzyme solution during travel through the inlet and outlet tubing of the chip 
was assumed to be negligible because the inner diameter of each tubing was large compared to 
the channel in the chip itself.  Therefore, to find θ, the volume of the chip as 0.0012 cm3 was 
divided by the volumetric flow rate associated with each shear rate tested, which was provided 
by the m-VROC™ software.  Although the shear rates tested increased from 5 to 200 ks-1, the 
γ’θ parameter for this method at all shear rates was 1.6 x 103.  In this model, a decrease in the θ 
parameter was compensated by an increase in γ’, resulting in the same γ’θ parameter for each 
rate tested.  Theoretically, equal amounts of protein degradation should be observed for each rate 
tested, assuming there is no effect of contact surface interaction with increasing surface exposure 
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time.  With a residence time ranging from ~8 milliseconds to 0.3 seconds, it is unlikely that 
surface interactions play a role in the degradation observed in this model. 
The rotational rheometer application of shear stress included an air-water interface, 
introducing a new factor which could cause enzyme degradation.  The rotational rheometer γ’θ 
parameter calculation included shear rates (γ’) of 5,500 or 1,000 s-1, which is multiplied by 600 
seconds as a total time for the stress exposure. Therefore, the γ’θ parameters from this model 
were 3 x 103, 3 x 105, and 6 x 105.   
The recirculate pumping model was the most complex system out of all experiments.  To 
simplify the model, the shear rate used for the γ’θ parameter was calculated utilizing the shear 
stress experienced at the wall (τw) of the tubing, representing the worst-case shear, as the shear 
stress experienced by the solution should be at the highest level on the wall in laminar flow16.  
Thus τw, can be calculated using Equation 2.   
Equation 2:   𝜏𝜏𝑤𝑤 =  
𝑅𝑅
𝐿𝐿
 ×  ∆𝑃𝑃
2
 
where, R is the internal radius of the tubing, L represents the tubing length, and ΔP is the 
pressure drop across the tubing.  ΔP was caculated using Equation 316, below. 
Equation 3:  ∆𝑃𝑃 =  8 × 𝜇𝜇 ×𝐿𝐿 ×𝑉𝑉
𝜋𝜋 𝑅𝑅4
 
where µ is dynamic viscosity, L is length of tubing, V is volumetric flow rate, and R is internal 
radius of the tubing.  The dynamic viscosity used was measured by the m-VROC™.  Finally, the 
shear stress at the wall, τw, can be related to shear rate by Equation 4. 





With a consistent RPM setting for the peristaltic pump, the shear rate will be identical for 
tubings of the same ID and length.  Therefore, to adjust the shear rate experienced by the system, 
two different inner diameter (ID) tubings were used (i.e., ID = 3.2 mm and 1.6 mm).  
Conveniently, these are also common tubing sizes used in fill-finish manufacturing practices.  
Additionally, the γ’θ parameter was adjusted to cover a very large range by varying the time 
recirculated.  The final calculated γ’θ parameters for the tubing recirculation model of this study 
for both tubing sizes can be seen in Table 3 (see below).   A high-level overview of the results 
from each of the models in terms of each analytical method’s ability to measure changes induced 
into the system were summarized in Table 4.  
  
C.2. m-VROC™ Results 
The effect of a γ’θ parameter of 1.6 x 103 was investigated using DLS by plotting shear rates 
(γ’) vs. Z Average (nm) and shear rates vs. polydispersity index (Figure 1a).  Shear rates tested 
ranged from 5,000 s-1 to 200,000 s-1 in a single experiment at 20 °C.  There were no changes 
observed in both Z Average and polydispersity index at various shear rates using m-VROC™ 
method (Figure 1a), indicating no measurable global destabilization during the specific contact 
and stress application.  The formation of dimer in solution during stress at different shear rates 
was also monitored by SEC (Figure 1b).  The result showed that there was no change in the 
dimer percent area as the shear rates increased.   
The stressed enzyme solution was also analyzed for changes in secondary structure using CD 
(Figure 2a) across all shear rates tested.   Spectra were collected from 285–195 nm, and the 
presence of two molar ellipticity minima at 208 nm and 220 nm indicate α-helical secondary 
structure.  Qualitatively, no change in conformation appear when exposed to different shear rates 
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experienced by this model, as indicated by the Figure 2a overlay.   Lastly, the effect of shear rate 
on SVP formation was tested using the MFI (Figure 2b).  Total subvisible particle did not show 
any increase with an increase in shear rate applied to the solution.  The overall SVP 
concentration hovered around the method’s LOD (200 particles/mL), indicating very low levels 
of SVP’s.  Because these solutions were clear upon visual inspection, it can be concluded that no 
higher-order insoluble aggregation occurred during the m-VROC™ application of a shear stress 
to the solution.   Results from all methods are consisent, and support the claim that a γ’θ 





Table 3. γ’θ parameters calculated for pumping experiments 
Time  
(s) 
1.6 mm Tubing  
γ’θ 
3.2 mm Tubing  
γ’θ 
900 1.3E+06 5.1E+05 
3600 5.1E+06 2.1E+06 
7200 1.0E+07 4.1E+06 
10800 1.5E+07 6.2E+06 
14400 2.0E+07 8.2E+06 
 
 
Table 4. Methods of analysis and their produced response 

























Secondary Structure (CD) -  - - 












































P o l y d i s p e r s i t y  I n d e x
Z - A v e r a g e
1 × 1 0 0 3 1 × 1 0 0 4 1 × 1 0 0 5 1 × 1 0 0 6
9 7 . 0
9 7 . 5
9 8 . 0
9 8 . 5
9 9 . 0
9 9 . 5



























D i m e r




Figure 1. Effect of shear on the physical properties of the enzyme evaluated using m-VROC™ 
experiment. (a) Overlayed graphical representation between polydispersity index and Z average 
from dynamic light scattering experiments. (b) Overlayed of between % monomer and dimer 
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Figure 2. The effect of stress at different shear rates on neat enzyme solution evaluated using 
m-VROC™. (a) The effect on the secondary structure of the enzyme was measured by CD 
absorption. (b) The effect on total the concentration of subvisible particles of neat protein 
solution was determined by MFI.   
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Figure 3. The effect of shear on the enzyme was measured using the rotational rheometer at both 
20 °C and 30 °C.  Normalized result to initial values from DLS testing: (a) hydrodynamic size as 
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Figure 4. Results from rotational rheometer experiments at both 20 °C and 30 °C (a) SEC-HPLC 
% Area dimer.  (b) MFI values for neat protein solution across all γ’θ values tested. 
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Figure 5. (a) Qualitative overlay of CD spectra, for highest stress scenarios by the rotation 
rheometer model. (b) Relative amounts of α-helical content, in terms of fraction helical (fH).   
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Figure 6. Effect of shear using the Rotational Rheometer as observed using reversed-phase 
HPLC. Post peak % area, shown vs. shear rate applied at both 20 and 30 °C.    
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C.3. Rotational Rheometer Results 
The rotational rheometer experiments were carried out to model an applied shear stress with 
the addition of an air-solution interface. The results produced low responses measured overall, as 
seen in Figures 3–6.  A small response was observed initially at 20 °C test conditions, so 
additional experimental replicates (n = 3) were performed to probe whether the responses were 
significant and reproducible.  The rotational rheometer studies were also repeated at 30 °C, in 
attempts to exaggerate any instability introduced by this model.  The results showed that an 
increase of 10 °C in temperature did not produce a significant instability across γ’θ parameters 
tested.   
DLS analytical results can be seen in Figure 3a–b for both temperatures tested across γ’θ 
tested.  When the Z average values were normalized to initial and averaged over 3 separate 
experiments, the result did not show a trend of signal increase with an increase in γ’θ parameters 
or with an increase in temperature.  Normalized PdI shown in Figure 3b also displayed no 
change from initial, indicating that the rotational rheometer model did not cause significant non-
native destabilization or aggregation as measured by light scattering.   
SEC HPLC normalized dimer % area vs. increasing γ’θ are plotted in Figure 4a.  The 20 and 
30 °C linear regression analyses did not produce a slope significantly differ from zero, with p-
values of 0.2472 and 0.7859, respectively.  The linear regression analyses also revealed that the 
data for 20 and 30 °C were not significanly different from each other, with a p-value of 0.1874.  
SEC HPLC did not detect soluble enzyme aggregation or destabilization resulting from the 
rotational rheometer model experiments at either temperature.   
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Figure 4b displays the MFI SVP concentration vs. increasing γ’θ parameter and it illustrates a 
slightly positive correlation with γ’θ parameter; however, after statistical analysis the positively 
trending slopes were not significantly different from zero (p-values ≥ 0.0904).  Additionally, the 
20 and 30 °C lines were determined to not be significantly different from each other, with a 
p-value of 0.7764.  Thus, it indicates that any observed fluctuations in SVP count by MFI can be 
explained due to random variance in the method.  SEC, DLS and MFI have been established as 
orthoganol techniques to characterize aggregate particles of varying sizes.  The results from these 
methods did not produce appreciable changes with increasing γ’θ, indicating that the rotational 
rheometer experiments, with the addition of an air-interface and reaching higher γ’θ parameters 
than the m-VROC™ model, did not induce measureable colloidal instability for this enzyme 
formulation. 
CD was performed to evaluate whether there were global secondary structural changes in the 
enzyme during stressed conditions across γ’θ parameters at either experimental temperature 
(Figure 5a–b).  As seen previously in the m-VROC™ results section (Figure 2a.), the enzyme 
contains α-helical secondary structure as indicated by the double minima at 208 and 222 nm 
(Figure 5a).  Qualitatively, a comparison of the full spectral overlay for the initial and highest γ’θ 
at both 20 and 30 °C  do not indicate visible difference from the initial spectra.  For a 
quantitative comparison of the CD spectra upon increased γ’θ, the α-helical content (fH)  was 
calculated using the following calulation17: 
[𝜃𝜃]222 =  −30,300 𝑓𝑓𝐻𝐻 − 2340 
where [θ]222 is the mean residue ellipticity at 222 nm.  Figure 5b shows fH for each of the stressed 
biotherapeutic conditions and compared to initial in green.  No significant changes in the helical 
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structure from initial, as indicated by a series of one-way ANOVA tests, all resulted in p-values 
of 0.6242 or higher.  CD was not able to resolve destabilization in secondary structure occurring 
from application of a shear stress using a rotational rheometer for this enzyme solution.    
To evaluate the presence of chemical modifications to the enzyme, the RP-HPLC method 
was used to monitor % area of the post peak (Figure 6a–b).  Figure 6a displays the raw post peak 
area % vs. shear rate applied for both 20 and 30 °C.  Linear regression analysis of the 20 and 
30 °C post peak % area data show that either slope are not significantly non-zero with a p-values 
of 0.0858, and 0.1625, respectively.  Additionally, the 20 and 30 °C values are not significantly 
different from each other, p-value of 0.4227.  The RP-HPLC results corroborate all the other 
analytical results to show that the rotational rheometer, at two different temperatures tested with 
reaching a maximum γ’θ of 6 x 105, did not induce measureable instability in the enzyme 
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Figure 7. Bulk properties of the enzyme solution during recirculated pumping between 0 and 4 h 
through 1.6 mm ID tubings from PureWeld®XL, Sani-Tech®STHT, Sani-Tech®Ultra, and 
PharMed®BPT (n = 4). (a) Turbidity, (b) Z average, and (c) polydispersity index measurements 
after recirculating neat protein solution and diluted with 30 x aCSF buffer.  Non-soluble aggregates 
removed using a 0.22 µm PVDF filter prior to analysis by DLS.   
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Figure 8. Bulk properties of the enzyme solution during recirculated pumping between 0 and 4 h 
through 3.2 mm ID tubings from PureWeld®XL, Sani-Tech®STHT, Sani-Tech®Ultra, and 
PharMed®BPT (n = 4). (a) Turbidity, (b) Z average, and (c) polydispersity index measurements 
after recirculating neat protein solution and diluted with 30 x aCSF buffer. Non-soluble aggregates 





C.4. Recirculated Pumping Model Results 
The pumping model simulates the transport of the enzyme solution via four different tubings: 
PureWeld®XL, Sani-Tech®STHT, Sani-Tech®Ultra, and PharMed®BPT at two inner diameters 
(i.e., ID = 1.6 and 3.2 mm).  These models reached the highest γ’θ parameter range (Table 3) and 
added interfacial complexity by using various tubing surfaces described in Table 4.  The most 
obvious effect of pumping was the visually observed insoluble flocculated protein aggregates in 
the solution.  Thus, turbidity of the solution was measured at 550 nm absorbance to quantify the 
property of the bulk solution throughout the experiment upon observation of visual aggregates 
(Figures 7a and 8a).  The results all showed a significant, non-zero linear trend of increasing 
turbidity with time recirculated for all four tubing types at both sizes, with p-values  ≤ 0.006.  
PharMed®BPT tubing performed the worst followed by PureWeld®XL tubing at both ID’s tested.  
The silicone tubings, Sani-Tech®STHT and Sani-Tech®Ultra, perform much better than the 
thermoplastic elastomer tubings for identical experiments and are indistinguishable from each 
other.   
Turbidity is a measurement of the bulk particulate properties of a system, similar to DLS 
measurements.  However, for DLS measurements the enzyme solutions were diluted and filtered 
using a 0.22 µm PVDF filter to effectively limit the size scale of analysis and mitigate the 
intense light scattering caused by large insoluble aggregates.  Interestingly, regardless of the 
tubing ID, the observed DLS results from each tubing trended incredibly closely to each other 
(Figures 7b and 8b).  It appears that tubing chemistry dictates the Z-Average outcome over time 
pumped.  Additionally, the DLS data corroborates with the turbidity results in tube ranking.  
PharMed®BPT and PureWeld®XL tubings caused the most dramatic increases in hydrodynamic 
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size, while the silicone tubings produced much slower and overall lower increases in 
hydrodynamic size.  
The polydispersity index (PdI) in Figures 7c and 8c illustrate a similar trend with the Z-
average results.  After one hour of pumping, the PharMed®BPT sample reached essentially a PdI 
of one, indicating the presence of many differently sized particles in solution.  Interestingly, the 
PdI values of  these samples fell back towards a monodisperse system over time pumped, 
suggesting that the aggregates either coalesced into a single large enzyme aggregate or that they 
became insoluble and could not be detected either due to their removal during the 0.2 µm 
filtration prior to testing, or their settling to the bottom of the measurement cell during 
measurement.  The PureWeld®XL pumped samples follow a similar trend, but after two hours of 
pumping, indicating either that the enzyme solution appears slighty more stable when exposed to 
pumping in PureWeld®XL tubing than PharMed®BPT or that they could be progressing through 
different mechanisms of aggregation.  The Sani-Tech® silicone tubing PdI data could only be 
distinguished from each other in the PdI result sets, with the Ultra producing a slightly more 
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Figure 9. Total SVP concentrations measured after recirculation in 1.6 mm ID tubings in (a) aCSF 
buffer solution (n = 3) and (b) enzyme solution (n = 4).  Tubing type are indicated by color 
including 1.6 mm ID Sani-Tech®Ultra (green), 1.6 mm ID PureWeld®XL (red), 1.6 mm ID Sani-
Tech®STHT (orange) and 1.6 mm ID PharMed®BPT (blue).    
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Figure 10. Total SVP concentrations measured after recirculation in 3.2 mm ID tubings in (a) 
aCSF solution (n = 3) and (b) biotherapeutic enzyme solution (n = 4). Tubing type are indicated 
by color including 3.2 mm ID Sani-Tech®Ultra (green), 3.2 mm ID PureWeld®XL (red), 3.2 mm 
ID Sani-Tech®STHT (orange) and 3.2 mm ID PharMed®BPT (blue).   
Figures 9–10 show the mean and standard deviation observed for total SVP concentration 
from all recirculation study replicate experiments.  aCSF buffer replicates (n = 3) were added to 
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these experiments to investigate only the effects of tubing degradation, and were indicated in 
Figure 9a and 10a.  Both sizes of PharMed®BPT tubing consistently produced the highest SVP 
counts of all tubings tested for both aCSF and enzyme recirculated solutions.  PureWeld®XL 
tubing produced a dramatic difference in SVP counts between the 1.6 mm ID tubing and the 
3.2 mm ID tubing in the case of aCSF solution, indicating that the smaller 1.6 mm ID with the 
higher flow rate, leads to a higher incidence of tubing shedding than the 3.2 mm ID tubing.  
aCSF solution pumped through both PharMed®BPT and PureWeld®XL tubing reached an SVP 
concentration maximum threshold after approximately 1 hour.  aCSF buffer solution pumped 
with silicone Sani-Tech® tubings produced remarkably low SVP’s overall in comparison to the 
PharMed®BPT and PureWeld®XL using particles with 1–100 micron size range. This indicates a 
very low occurrence of tubing shedding in this particle size range.   
MFI allows not only for the quantification of SVPs, but also captures images of each particle 
for qualitative morphological analysis.  Theoretically, light proteinaceous particulate could be 
separated from darker tubing particulate caused by material shedding.  However, from early on 
in these experiments, the resulting total particulate concentrations were too high and too diverse 
to reliably depend on morphological parameters to separate tubing SVPs from a mixture of 
tubing SVPs and enzyme aggregate SPVs.  Therefore, the information gleaned from the data 
presented in Figures 9a. and 10a. serves as a control to understand the quality of the tubing itself.  
Clearly, the silicone tubings outperform the PharMed®BPT and PureWeld®XL tubing in the 
experiments with 1.6 ID tubings. In contrast, the experiments with a 3.2 mm ID tubing, 
PharMed®BPT tubing distinguishes itself as the worst performer in terms of SVP release in the 
presence of aCSF solution alone.    
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The pumped enzyme solutions, as seen in Figures 9b. and 10b., contain both shed tubing 
particles and SVPs resulting from insoluble protein aggregation.  Overall, the solution pumped 
through 1.6 mm ID (Figure 9b) tubings trended slightly higher in SVP counts than the 3.2 mm 
ID tubings (Figure 10b), even with the different experimental volumes are taken into account.  
Similar to the aCSF solution results, the PharMed®BPT trended as the highest generator of SVP 
counts at both tubing sizes.  The second highest SVP counts were again attributed to the 
PureWeld®XL tubing.  Additionally, none of the recirculated enzyme solutions appeared to reach 
a threshold in SVP concentration as observed in the aCSF buffer experiments; however, a 
continued growth of  SVP concentration was observed over time.  Interestingly, although the 
3.2 mm ID PureWeld®XL tubing for the aCSF buffer (red, Figure 10a.) showed a low level of 
SVP, the recirculated enzyme solution still resulted in high SVP counts. 
  The recirculated enzyme solution experimental results for SVP show only slight differences 
between the two silicone tubings.  In the highest-stressed condition produced by the 1.6 mm ID 
tubing (Figure 9b.), Sani-Tech®Ultra tubing (green) trends to have slightly lower in SVP’s than 
Sani-Tech®STHT tubing (orange).  This trend was also observed for the 3.2 mm ID tubing 
recirculation replicates (Figure 10b.), indicating that the enzyme interaction with the tubing 
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Figure 11. SEC high molecular weight species (HMWS) from enzyme solution recirculation 
experiments (a) 1.6 mm inner diameter (ID) tubing, and (b) 3.2 mm ID tubing of the same tubing 






Figure 12. Recirculated enzyme solution representative of the worst-case in SEC chromatogram 














3.00 3.50 4.00 4.50 5.00 5.50 6.00 6.50 7.00 7.50 8.00 8.50 9.00 9.50 10.00 10.50 11.00 11.50 12.00
HMWS Monomer 
Dimer 
















1 . 6  m m  I D  P u r e W e l d

X L
1 . 6  m m  I D  S a n i - T e c h

 S T H T

1 . 6  m m  I D  S a n i - T e c h

 U l t r a
1 . 6  m m  I D  P h a r M e d

 B P T
36 
 
material experiments.  The black trace represents PharMed®BPT tubing, and the red trace 
represents PureWeld®XL tubing material.       
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The SEC-HPLC method was employed to quantify the amount of soluble higher-order 
aggregates (% HMWS), dimer, monomer, and fragments in solution caused by pumping through 
various tubing experiments.  The results provided a more resolved investigation of heterogeneity 
of the system than DLS, and is quantified by % Area at 214 nm.  Figures 11a–b displayed the 
results from both tubing sizes and there was no trend observed in the Sani-Tech® tubings. In 
contrast, sharp increases were observed in the PureWeld®XL and PharMed®BPT tubings.  In 
fact, PharMed®BPT tubing caused the most dramatic increase in HMWS content with detected 
levels of HMWS found after only 15-minutes of recirculated pumping.   HMWS % area in 
PureWeld®XL also showed growth over time during recirculation process, but the HMWS 
became detectable after 1 hour.  Overall, the smaller tubing ID experiments (Figure 11a) 
produced higher levels of HMWS than the larger tubing ID (Figure 11b), which could be 
attributed to, at least in part, the higher shear experienced at the tubing wall in 1.6 mm ID tubing.  
Figure 12 displays an overlay of SEC chromatograms for the effects of the 4-hour 
recirculation on the enzyme solution using PharMed®BPT (black) and PureWeld®XL (red) 
tubings.  The HMWS is the first peak to elute followed by a poorly resolved dimer at the 
shoulder of the monomer peak.  The results from Sani-Tech® tubings were not included in Figure 
12 because they did not produce a significant level of HMWS.  There was no observable enzyme 
fragment in the recirculated samples.  Additionally, the dimer peak % area remained constant 
through all the experiments completed in this work.  Therefore, the most interesting find was the 
growth of the HMWS peaks in PharMed®BPT and PureWeld®XL tubings because the HMWS 
changed by growing in % Area with pumping time.  
It is also interesting to note that the HMWS consistently generated by pumping with either 
the PharMed®BPT or PureWeld®XL appear to be slightly different species, as indicated by the 
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peak shape.  The PharMed®BPT pumped samples produced a more gaussian peak, indicating a 
single species, while the PureWeld®XL HMWS peak always appeared bimodal.  The HMWS 
produced in the PureWeld®XL tubing forms a more polydisperse range of higher order 
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Figure 13. Quantified post peak % area from recirculation experiments (a) 1.6 mm inner 
diameter (ID) tubing and (b) 3.2 mm ID tubing of the same tubing types.  All data reflect 
integrated chromatograms at 214 nm. 
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Figure 14. α-helical content (fH) from recirculation experiments (a) 1.6 mm ID tubing (filled 
squares) and (b) 3.2 mm ID tubing (open squares) of each tubing type. Tubing type are indicated 
by color including Sani-Tech®Ultra (green), PureWeld®XL (red), Sani-Tech®STHT (orange) and 
PharMed®BPT (blue).  CD experiments completed for two independent experiments and only the 
2-hour and 4-hour time points were tested.  
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The RP-HPLC method was employed to screen for possible chemical degradation caused by 
a combination of shear forces involved with pumping and exposure to various tubing surface 
chemistries.  Specifically, an increase in post peak has been described to indicate changes in 
protein chemical stability (data not shown).  The post peak was monitored throughout all the 
experiments and the data can be seen in Figure 13a and b for both tubing sizes tested.  No 
significant growth in post peak was observed during pumping time; the linear regression analysis 
for every curve’s slope showed no significant change from zero with p-values all ≥ 0.0270.  The 
chemical modifications during shear and interfacial stresses were evaluated using RP-HPLC and 
there was no significant effect found across all models. Thus, the remainder of this work was 
focused on physical stability of the biotherapeutic enzyme.   
CD experiments were used to assess the structural comparability of the recirculated enzyme 
solution across the various tubings.  As the solutions were not filtered prior to far-UV CD 
measurements, the goal was to gain insight into the global secondary structure content in 
solution, which would also include higher order aggregates.  In Figure 14a and b, the initial α-
helical content (fH) is plotted with 2-hour and the worst-case 4-hour recirculated solution.  For all 
experiments, the resultant changes are insignificant from zero time point to 4-h time point with 





The results exhibit the importance of examining physical stability of an enzyme during fill-
finish processing in the absence of stabilizing excipients.  Several different models were used to 
separate the effect of shear and interfacial interactions.  Hydrodynamic flow effects alone did not 
appear to damage the enzyme in the m-VROC™ model, and neither did the addition of an air 
interface in the rotational rheometer model of shear stress.  The recirculation pumping model, 
however, produced dramatic measurable changes in the enzyme’s physical stability.  Results 
indicate that physical stability of the enzyme solution were affected most significantly by 
enzyme-tubing surface interactions with less contribution from hydrodynamic forces on the 
enzyme structure.   
In the recirculated pumping experiments, it is clear that Platinum-cured silicone surfaces 
(Sani-Tech®Ultra & Sani-Tech®STHT) produced drastically lower degradation effects than that 
of the thermoplastic elastomer (PharMed®BPT and PureWeld®XL) tubings.  In manufacturing, 
PharMed®BPT tubing is frequently used in conjunction with peristaltic pumps due to its 
preferred durability, chemical resistance, and biocompatibility.  However, the highest levels of 
SVP’s were found in PharMed®BPT tubing pumped with aCSF buffer solution alone (Figures 9a 
& 10a), indicating that particles were shed directly from the tubing.  PharMed®BPT tubing is a 
polypropylene based matter manufactured with mineral oil and other unknown blend materials 
that are hydrophobic in nature. The overall property of the tubing surface is hydrophobic; thus, it 
is necessary to coat it with hydrophilic poly-vinyl alcohols (PVA)18.  The generation of 
particulate during recirculation of the aCSF buffer could be due to the disintegration of the 
hydrophilic coating, compromising the tubing by exposing its hydrophobic surface, and possibly 
promoting undesireable hydrophobic interations in the enzyme solution.  Not only would the 
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tubing interface be hydrophobic, but the shed particles would be, as well.  The released 
hydrophobic particles could act as aggregation nucleators, which is alarming because the use of 
this tubing is prolific in filling of many biotherapeutic products.   
The PureWeld®XL tubing with 1.6 mm ID consistently produced a high SVP concentration 
in recirculated aCSF buffer solution at the highest volumetric flow rates (Figure 9a).  In contrast, 
no overwhelming increase was observed in SVP’s at 3.2 mm ID PureWeld®XL tubing (Figure 
10a).  A possible explanation for the difference in SVP amounts could be due to the difference in 
volumetric flow rates between the two tubing sizes. The rate differences led to a difference in 
pressure drop (ΔP) from 4.2 x 106 mPa for 1.6 mm ID to 0.9 x 106 mPa for 3.2 mm ID tubings.  
The higher pressure in a smaller tubing generates higher friction between the solution and the 
tubing surface, leading to the sloughing-off of particles from the tubing surface into solution.  
However, a difference of pressure drops may not be the only factor affecting the particle 
shedding from the surface.  Another explanation originates from the physical appearance of the 
tubing surface itself.  A rougher surface may cause important differences in the flow or friction 
interactions between the pumped liquid and the tubing wall, and may cause higher particle 
shedding.  In a similar experiment done by Saller, et al., it was noted that surface roughness was 
a determining factor for particle shedding from silicone tubing as measured by 3D laser scanning 
microscopy, and that higher roughness of the suface led to higher production of particles.19  If for 
any reason the internal tubing surface varied between the two ID sizes, differences in surface 
roughness could offer an explanation for the difference in shedding behavior, with the pressure 
drop differences only confounding the end result.  Additionally, continuous peristaltic 
recirculation pumping for up to 4-hours visually deformed the external surface of every type of 
tubing in these studies, indicating the friction between the the tubing with the peristaltic pump 
44 
 
rollers could be a large source of SVP measured.  Internal spallation could also occur due to 
squeezing action by the rollers; with the smaller tubing exhibiting more spallation, as there 
would be less surface area in the pumphead, and therefore higher forces involved pressing onto 
the tubing material.  An important consideration from these data is the fact that the two tubing 
sizes exhibited different behaviors. This indicates that individual testing with this particular 
material should be always be performed and the use of PureWeld®XL as a candidate for fill-
finish should be approached with caution.  
Additional limitations should be considered as well for the PureWeld®XL, especially in 
terms of behavior of the tubing in the pumphead.  In these studies, the PureWeld®XL tubing was 
difficult to keep in the pumphead during pumping process due to its smooth surface; the tubing 
continuously traveled through the pumphead, causing stops in the experiment for tubing 
repositioning.  Another reason that PureWeld®XL should perhaps be disregarded in 
consideration as a candidate for a manufacturing operation involving peristaltic pumping. 
The large increases in SVP caused in enzyme solution by tubing materials can be explained 
by two main pathways.  First, a hydrophobic thermoplastic elastomer surface alone can pose a 
risk for inducing aggregation.  A native enzyme could experience a reversible and non-specific 
binding event to the surface via interaction with the hydrophobic core of the enzyme, which can 
induce partial unfolding in solution.20  Once the conformationally compromised enzyme is 
released back into solution, it is susceptible to subsequent oligomerization processes.  
Additionally, because shed SVP’s the from surface coating disintegration could be hydrophobic 
in nature, these particles can act as heterogeneous nucleation sites for enzyme aggregation away 
from the tubing surface.  Although the sub-visible range shed particulates could be filtered from 
the product, the generated soluble aggregates (i.e., HMWS) could pass through a sterile filter, 
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and would be included in the final drug product. The presence of soluble HMWS in the final 
product increases the risk for subsequent aggregation events during shelf-life including 
shipping/handling prior to administration of the product.  Thus, there is need for close 
monitoring of the product to ensure a safe and efficacious drug on stability.      
A similar trend was observed for concentration of SVP’s in the enzyme solution after 
recirculation with thermoplastic elastomer tubings; in this case, SVP concentrations were much 
higher than platinum-cured silicone tubings (Figures 9b & 10b).  On one hand, it is easy to 
understand this phenomenon as the thermoplastic elastomer material with buffer alone produced 
SVP’s; therefore, the SVP’s are also expected to be present in the recirculated enzyme solution.  
However, the enhanced particulate growth in the enzyme solution was far past what was seen in 
aCSF buffer recirculated solution.  This enhancement could be a combination of several factors 
with the largest factors being protein interactions or collisions with tubing surface or shed 
floating particulates.  At the 4-hour time point for both tubing sizes, the concentration of 
aggregates were higher in PharMed®BPT and PureWeld®XL compared to the other two tubings 
(Sani-Tech®Ultra & Sani-Tech®STHT) as reflected globally by turbidity (Figures 7a & 8a) and 
Z-average (Figure 7b & 8b) measurements.  The levels of aggregation at the 4-hour time point 
for both Sani-Tech®Ultra & Sani-Tech®STHT remained low in all recirculation experiments.  A 
similar trend has also been reported by Mahajan et al. between Platinum-cured silicone tubing 
and polypropylene based tubing with USP mineral oil in recirculation experiments performed 
with virus-like particles adsorbed to adjuvant21.  The data from Mahajan et al. showed that 
pressure at 0–3.5 psi was not a factor in causing increased particle size change (%) but the 
observed dramatic increase in particles was caused by tubing material9.  This study showed that 
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the silicone tubing outperformed the polypropylene material by producing much lower increases 
in particle size regardless of pressure.     
These observed optical data were also supported by SEC (Figure 11), showing that both 
PharMed®BPT and PureWeld®XL produced multimer peaks which were not detected in the 
silicone tubings.  The HMWS present from PharMed®BPT and PureWeld®XL were even 
different from each other as shown in Figure 12.  The difference in the multimer peaks could 
indicate that the mode of degradation experienced as a result of elastomer surface could depend 
on tubing type; thefore indicating that tubing chemistry influences the physical degradation 
observed.  In an extractable/leachable study conducted by Jenke, et al. it was shown from 
simulated use experiments that silicone tubings produced a different leachable profile than 
Santoprene-type tubings, with the Santoprene introducing alkylphenols and decomposition 
products of Irganox-type antioxidants22.  Athough the silicone tubings and Santoprene-type 
(thermoplastic elastomer) tubing identities and manufacturers were not disclosed, it is evident 
that the elastomer tubing leachables, as they are unique from silicone, could also be implicated as 
heterogeneous nucleating agents in solution, possibly leading to the observed soluble HMWS.  
The polydispersity in the enzyme solution was also an indicator of unique aggregation 
kinetics produced by either the PharMed®BPT and PureWeld®XL tubings (Figures 7c & 8c).  
The enzyme solution in PharMed®BPT tubing reached a maximum PdI after only 15 minutes of 
recirculation compared to the 2 hours in the PureWeld®XL tubing.  For both PharMed®BPT and 
PureWeld®XL tubings, the polydispersity dropped after reaching a maximum. This observation 
was presumably due to the precipitation of larger aggregates that were filtered out of the solution 
prior to analysis with the 0.22 µm filter.      
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One of the goals of this work was to not only point out the inherent risk involved with 
formulating an ERT in the absence of stabilizing excipients, but also to highlight that certain 
risks can be mitigated by implementing proper processes.  One of the most simplistic mitigation 
strategies is to use the most appropriate tubing chemistry from the beginning during the process 
design.  In addition, enzyme degradation data could be used to convince tubing manufacturers to 
release additional information about tubing surface chemistry to help elucidate problems of 
protein instability. This would allow pharmaceutical scientists to narrow the selection of tubings 
that are appropriate for a specific biotherapeutic protein without such exhaustive experimental 
studies; however, because the unique protein structure plays such a large role in protein surface 
interactions, individual tubing evaluation should still be completed.  These experimental data 
should help drive decisions in the fill-finish process when working with entities within or outside 
an organization.   
Often, tubing materials are selected based on in-house availability or preference for 
manufacturing convenience without a holistic consideration for compatibility with the 
biotherapeutic being delivered.  Especially in the absence of stabilizing excipients, the results 
presented here underscore the need to investigate the possibility of inherent interfacial 
incompatibility that could exists between tubing surface and enzyme.  One could imagine that a 
soluble aggregate below 0.22 µm would survive sterile filtration, and exist in the final drug 
product, threatening to be a destabilizing force for long-term stability.  In a previous study by 
Saller et al.19, it was reported that silicone tubing used in recirculation studies produced around 
200 nm particles, which could pass through the sterile filtration process.  Irrespective to the 
production of nano particulate, it was demonstrated that the silicone tubing particulate did not 
show an additive effect to the degradation of two separate mAb formulations23.   However, it 
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should also be noted that these formulations included stabilizing agents such as sugar and 
nonionic surfactants to mitigrate deleterious surface interactions.  A similar spiking study with 
long-term stability may be an important piece of information for an enzyme formulation with no 
stabilizing sugars and surfactants.  Protein stability in terms of efficacy alone is only one piece of 
the equation, it is also imperative to demonstrate safety of the product, because aggregate species 
can be responsible for adverse immune responses24.  It is a simple and easy solution to replace 
incompatible tubing with a compatible tubing to produce a safer and more stable drug product.  
An interesting set of follow-up experiments to this work would be to add a sugar or 
surfactant to observe whether it would suppress the appearance of the multimer peak.  A study 
conducted using a cone and plate rotational rheometer to apply a shear stress by Patapoff and 
Esue showed that the addition of polysorbate 20 reduced the formation of insoluble aggregates25. 
The study concluded that the decreased in aggregation was due to protection of protein form both 
air-water interface and shear stress25.  Although aggregation was not observed in the rotational 
rheometer method in these experiments, it has also been shown that nonionic surfactants can 
prevent aggregation caused by many types of interfacial interactions other than the air-water 
interface interaction1.  Therefore, it would be interesting to observe an increased in stability of 
our enzyme with added surfactants to further support the idea that the tubing material interface 
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Figure 15. SVP concentration from MFI compared across models.  Solid bars represent results 
from enzyme solution experiments, the rotational rheometer (black) had a γ’θ value of 6 x 105.  
Colored striped (aCSF buffer), and solid (enzyme solution) bars represent recirculation tubing 
experiments at 3.2 mm ID, with a γ’θ value of 5 x 105:  Sani-Tech®Ultra (green), Sani-Tech®STHT 
(orange), PureWeld®XL (red), and PharMed®BPT (blue). 
 
Clearly from the recirculation experiments, the Platinum-cured silicone tubings tested here 
are the superior for processes involving this enzyme solution without excipients. This finding 
could most likely be extended to other biopharma products.  Theoretically, the rotational 
rheometer experiment at a γ’θ value of 6 x 105 could be most closely compared to the 3.2 mm ID 
tubing experiments at the 15-minute time point with a γ’θ value of 5 x 105 (Figure 15).  In Figure 
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15, it is clear that the rotational rheometer results were not comparable in SVP concentration to 
that of recirculation experiments.  The difference indicate that interfacial phenomena contributes 
greatly in the formation of SVP aggregates.  It should also be noted that the use of the γ’θ 
parameter could be too simplistic to compare between the models because the recirculation 
model involves stresses generated by tubing, peristaltic pumping, and other forms of stresses 







Three unique models were used to understand various stresses involved with the fill-finish 
process for an enzyme therapeutic.  In this thesis, an m-VROC™ differential pressure 
viscometer, a rotational rheometer, and a peristaltically pumped recirculation model with 
common tubing materials were used to that end.  The m-VROC™ and rotational rheometer 
experiments did not appear to introduce instability to the tested enzyme molecule system, 
indicating that the levels of hydrodynamic stress in these methods were below the levels required 
for denaturation, even with the addition of an air-interface in the rotational rheometer testing.  
However, the peristatic recirculation model produced clear trends in colloidal enzyme stability.  
A ranking exists among the types of tubings studied in the recirculation experiments.  
PharMed®BPT and PureWeld®XL produced the highest SVP counts in both buffer alone and the 
enzyme solution and are not the appropriate choice in manufacturing and fill-finish operations 
for the enzyme tested.  These tubings have been shown to promote enzyme aggregation during a 
peristaltic pumping process, both soluble and insoluble aggregates were discovered.  The 
Platinum-cured silicone tubing perfomed the best in these recirculation experiments and are 
optimal for manufacturing and fill-finish operations without major difference between the two 
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